Newsbenzinga
Ultragenyx Gene Therapy For MPS IIIA Clears EMA Validation, Holds PRIME And Orphan Designations, Will Fall Under EU Joint Clinical Assessment
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…